Heating of Double Coldprecipitated Factor VIII Concentrate from Heparinized Plasma

  • C. Th Smit Sibinga
  • J. Notebomer
  • P. C. Das
Part of the Developments in Hematology and Immunology book series (DIHI, volume 15)


Factor VIII (FVIII) concentrates have been produced from heparinized plasma by double coldprecipitation. In clinical trials these FVIII concentrates have showed normal FVIII recovery and half-life in stable hemophiliac patients, and good hemostatic effect during acute surgical procedures in hemophiliac patients. It is a high-yielding (50%) freeze-dried product with specific activity of 0.5 to 0.8. Most of its protein content is due to fibrinogen and fibronectin [1]. Repeated exposure to FVIII concentrate carries the potential risk of virus infections such as hepatitis. Despite the fact that our product is derived from small pools [2] the recent publicity on HTLV III and AIDS has necessitated the introduction of a virus inactivation procedure on this material [3]. Heating was chosen since it is easily adaptable to our system. HTLV III seems to be exquisitely sensitive to heating at 56°G in the liquid stage [4]. Dry heating is also effective but requires a longer time and higher temperature, for instance 68°C for 24–48 hours [5,6], although 60°C for 10–30 hours may also be effective for dried FVIII concentrates [7,8].


Factor Viii Virus Inactivation HEPARINIZED Plasma Acute Surgical Procedure FVIII Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Smit Sibinga CTh, Das PC. Heparin and Factor VIII. Scand J Haematol 1984; 33(suppl 40): 111–22.Google Scholar
  2. 2.
    Smit Sibinga CTh, Das PC. Small pool versus large pool in plasma frac-tionation: Reevaluation of a concept. In: Smit Sibinga CTh, Das PC, Seidl S (eds). Plasma fractionation and blood transfusion. Martinus Nijhoff Publ. Boston/Dordrecht/Lancaster 1985: 43–6.Google Scholar
  3. 3.
    Anonymous. Blood transfusion, haemophilia and AIDS (editorial). Lancet 1984; ii: 1433–5.Google Scholar
  4. 4.
    Spire B, Dormont D, Barré-Sinoussi F, Montagnier K, Chermann JC. Inactiv-ation of lymphadenopathy associated virus by heat, gamma rays and ultraviolet light. Lancet 1985; i: 188–9.CrossRefGoogle Scholar
  5. 5.
    Levy JA, Mitra G, Mozen MM. Recovery and inactivation of infectious retro-virus added to Factor VIII concentrate. Lancet 1984; ii: 722–3.CrossRefGoogle Scholar
  6. 6.
    Levy JA, Mitra G, Mozen MM. Inactivation of wet and dry heat for AIDS associated retroviruses during purification from plasma. Lancet 1985; i: 1456–7.CrossRefGoogle Scholar
  7. 7.
    Petriciani JC, McDougal JC, Evat BL. Case for concluding that theat treated licensed anti haemophiliac Factor is safe from HTLV III. Lancet 1985; ii: 890–1.CrossRefGoogle Scholar
  8. 8.
    Fielding P, Nilsson IM, Hansson BG, Biberfeld G. Absence of antibodies to LAV/HTLV III in haemophiliacs treated with heat treated Factor VIII concentrate of American origin. Lancet 1985; ii: 832–3.CrossRefGoogle Scholar
  9. 9.
    Mozen MM, Louic RE, Mitra GA. Heat inactivation of viruses in anti haemophiliac factor concentrate. Presentation XVI international congress of the World Federation of Haemophilia, Rio de Janeiro, August 24–28, 1984.Google Scholar
  10. 10.
    Ellis BC, Stranski A. A quick and accurate method for the determination of fibrinogen in plasma. J Lab Clin Med 1961; 58: 477–8.PubMedGoogle Scholar
  11. 11.
    McLeod AJ, Dickson IH, Foster PR. Pasteurisation of coagulation factor concentrates. Thromb Haemost 1983; 50: 432.Google Scholar
  12. 12.
    McLeod AJ, Cuthbertson B, Foster PR. Pasteurisation of Factor VIII and IX concentrates. Abstr. 18th congr. ISBT Munich. Karger Basel 1984: 34.Google Scholar
  13. 13.
    Uithof J. Optimalisation of Factor VIII preparation from heparinized plasma. Red Cross Blood Bank Groningen-Drenthe, 1985.Google Scholar
  14. 14.
    Kernoff PB, Miller EJ, Savidge GF, Machin SF, Dewar MS, Preston FE. Wet heating for safer Factor VIII concentrate. Lancet 1985; ii: 721.CrossRefGoogle Scholar
  15. 15.
    Colombo M, Mannucci PM, Carnelli V, Savidge GF, Gazengel C, Schimf K. Transmission of non A non B hepatitis by heat treated Factor VIII concentrates. Lancet 1985; ii: 1–4.CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston. 1986

Authors and Affiliations

  • C. Th Smit Sibinga
  • J. Notebomer
  • P. C. Das

There are no affiliations available

Personalised recommendations